Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090987 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00090987 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 30 participants.
The verdict
NCT00090987, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related Kaposi's sarcoma.
Interventions
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-06 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090987
The ClinicalTrials.gov registry entry for NCT00090987 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT00090987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090987 about?
NCT00090987 is a clinical study titled "Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma". RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related Kaposi's sarcoma.
What is the current status of trial NCT00090987?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-06. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00090987?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00090987?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.